Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC

Cancer Immunology Research

Volumn 5, Issue 5, 2017, Pages 417-424

  Tumeh, Paul C ^a   Hellmann, Matthew D ^b   Hamid, Omid ^c   Tsai, Katy K ^d   Loo, Kimberly L ^d   Gubens, Matthew A ^d   Rosenblum, Michael ^d   Harview, Christina L ^a   Taube, Janis M ^e   Handley, Nathan ^d   Khurana, Neharika ^d   Nosrati, Adi ^d   Krummel, Matthew F ^d   Tucker, Andrew ^a   Sosa, Eduardo V ^d   Sanchez, Phillip J ^a   Banayan, Nooriel ^a   Osorio, Juan C ^b   Nguyen Kim, Dan L ^e   Chang, Jeremy ^a   Shintaku, I Peter ^a   Boasberg, Peter D ^c   Taylor, Emma J ^a   Munster, Pamela N ^d   Algazi, Alain P ^d   Chmielowski, Bartosz ^a   Dummer, Reinhard ^e   Grogan, Tristan R ^a   Elashoff, David ^a   Hwang, Jimmy ^d   Goldinger, Simone M ^f   Garon, Edward B ^a   Pierce, Robert H ^g   Daud, Adil ^d   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Angeles Clinic and Research Institute   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g Oncosec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; IPILIMUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN S 100; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SECONDARY; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85018440802     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0325     Document Type: Article

References (41)

1. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
2. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
3. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
5. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
6. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
7. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
8. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016;17:299-308.
9. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
10. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
11. Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Lond Engl 2016;387:1540-50.
12. Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity 2016;44:1069-78.
13. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory responsewith B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
14. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064-74.
15. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
16. Daud AI, Hamid O, Ribas A, Hodi FS, Hwu W-J, Kefford R, et al. Abstract CT104: antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome. Cancer Res 2014;74(19 Suppl):CT104.
17. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
18. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
19. Blank CU, Haanen JB, Ribas A, Schumacher TN.CANCER IMMUNOLOGY. The "cancer immunogram." Science 2016;352:658-60.
20. Tsai KK, Loo K, Khurana N, Algazi AP, Hwang J, Sanchez R, et al. Clinical characteristics predictive of response to pembrolizumab in advanced melanoma. J Clin Oncol 33, 2015(suppl; abstr 9031).
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
22. Daud AI, Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 33, 2015(suppl; abstr 9005).
23. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18.
24. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32.
25. Calne RY. Mechanisms in the acceptance of organ grafts. Br Med Bull 1976;32:107-12.
26. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969;223:472-6.
27. Cantor HM, Dumont AE. Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature 1967;215:744-5.
28. Calne RY. Immunological tolerance - the liver effect. Immunol Rev 2000;174:280-2.
29. Qian S, Lu L, Fu F, Li Y, Li W, Starzl TE, et al. Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol 1997;158:4654-61.
30. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol 2013;14:996-1006.
31. Limmer A, Ohl J, Kurts C, Ljunggren H-G, Reiss Y, Groettrup M, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000;6:1348-54.
32. Limmer A, Ohl J, Wingender G, Berg M, Jüngerkes F, Schumak B, et al. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur J Immunol 2005;35: 2970-81.
33. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3:51-62.
34. John B, Crispe IN. Passive and active mechanisms trap activated CD8+ T cells in the liver. J Immunol 2004;172:5222-9.
35. Wang J-CE, Livingstone AM. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 2003; 171:6339-43.
36. Tu Z, Pierce RH, Kurtis J, Kuroki Y, Crispe IN, Orloff MS. Hepatitis C virus core protein subverts the antiviral activities of human kupffer cells. Gastroenterology 2010;138:305-14.
37. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016;315:1600-9.
38. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017;355:pii:eaaf8399.
39. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
40. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084-9.
41. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.